Six patients with the rare genetic disorder Fabry disease have filed a lawsuit against Cambridge, MA-based biotech company Genzyme (NASDAQ:[[ticker:GENZ]]) and Mt. Sinai Medical School over the handling of a rationing system for Genzyme’s Fabry treatment, agalsidase beta (Fabrazyme), the online publication Pharmalot reported yesterday. Genzyme, which is being bought by the French drug giant Sanofi-Aventis (NYSE:[[ticker:SNY]]) for $20.1 billion, started rationing its Fabry therapy after a temporary closure in 2009 of its Allston, MA, plant where the treatment is made. Mt. Sinai, of New York, is named in the lawsuit because it licensed the treatment to Genzyme and “went along with the rationing plan,” Pharmalot wrote.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
